Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER-targeted therapy in HER2 amplification-positive and HER2 mutation-positive amplification-negative patients.
MYC dysregulation in the progression of multiple myeloma.
Leukemia
Misund, Kristine K; Keane, Niamh N; Stein, Caleb K CK; Asmann, Yan W YW; Day, Grady G; Welsh, Seth S; Van Wier, Scott A SA; Riggs, Daniel L DL; Ahmann, Greg G; Chesi, Marta M; Viswanatha, David S DS; Kumar, Shaji K SK; Dispenzieri, Angela A; Gonzalez-Calle, Veronica V; Kyle, Robert A RA; O'Dwyer, Michael M; Rajkumar, S Vincent SV; Kortüm, K Martin KM; Keats, J Jonathan JJ; , ; Fonseca, Rafael R; Stewart, A Keith AK; Kuehl, W Michael WM; Braggio, Esteban E; Bergsagel, P Leif PL
Publication Date: 2020-01
Variant appearance in text: EGFR: 3038C>T; Ala1013Val